OBJECTIVES: DMTs to manage RRMS patients have traditionally been injectables. With the introduction of new oral DMTs, a better understanding of the shift in treatment patterns and their impact on patient disease burden is needed. The objective of this study was to assess the characteristics of RRMS patients taking injectable and oral DMTs in the EU (5EU: UK/France/Germany/Italy/Spain). METHODS: A multi-center retrospective chart-review study of RRMS patients was conducted in the 5EU in 4Q2014 to collect de-identified data on diagnosis, clinical status, and treatment patterns. Physicians were screened for duration of practice (≥3yrs) and patient volume (≥15 MS patients/mo) and recruited from a large panel to be geographically representative. Medical charts of the next 10 consecutive MS patients were abstracted. RRMS patients taking an injectable (INJ) or oral DMT were analyzed. RESULTS: CONCLUSIONS: In this cohort of RRMS patients, physicians initiated oral DMTs predominantly as second or third-line treatment, and these patients may have higher disease burden compared to those receiving injectable DMTs. Further research is needed to evaluate the observed treatment patterns and treatment sequencing strategies to alleviate patient burden.